ISSN 2306-5559 (print)
ISSN 2410-938X (online)
ISSN 2410-938X (online)
There is no conflict of interest.
1. Rizzetto M., Canese M.G., Arico S. et al. Immunofluorescence detection of new antigen-antibody system (delta/anti¬delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers // Gut. 1977. Vol. 18. № 12. P. 997–1003.2. Rizzetto M., Purcell R.H., Gerin J.L. Epidemiology of HBV-associated delta agent: geographical distribution of anti-delta and prevalence in polytransfusedHBsAg carriers // Lancet. 1980. Vol. 1. № 8180. P. 1215–1218.3. Rizzetto M., Shih J.W., Gerin J.L. The hepatitis B virus-associated delta antigen: isolation from liver, development of solid-phase radioimmunoassays for delta antigen and anti-delta and partial characterization of delta antigen // J. Immunol. 1980. Vol. 125. № 1. P. 318–324.1. Lozano R, Naghavi M, Foreman K, et al.. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012 Dec 15;380(9859):2095–2128. doi: 10.1016/S0140-6736(12)61728-0. PubMed PMID: 23245604. [PubMed] [CrossRef] [Google Scholar]2. Collaborators GBDCoD Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the global burden of disease study 2016. Lancet. 2017 Sep 16;390(10100):1151–1210. doi: 10.1016/S0140-6736(17)32152-9. PubMed PMID: 28919116; PubMed Central PMCID: PMCPMC5605883. [PMC free article] [PubMed] [CrossRef] [Google Scholar]3. https://doi.org/10.1111/j.1478-3231.2010.02320.xStéphaniePascarella, 4. Rizzetto M, Canese MG, Arico S, et al. Immunofluorescence detection of new antigen-antibody system (delta/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers. Gut 1977; 18: 997– 1003. CAS PubMed Web of Science® Google Scholar5. Rizzetto M, Canese MG, Gerin JL, et al. Transmission of the hepatitis B virus-associated delta antigen to chimpanzees. J Infect Dis 1980; 141: 590– 602.CAS PubMed Web of Science® Google Scholar6. Wang KS, Choo QL, Weiner AJ, et al. Structure, sequence and expression of the hepatitis delta (delta) viral genome. Nature 1986; 323: 508– 14. CAS PubMed Web of Science® Google Scholar7. Cross TJ, Rizzi P, Horner M, et al. The increasing prevalence of hepatitis delta virus (HDV) infection in South London. J Med Virol 2008; 80: 277– 82. PubMed Web of Science® Google Scholar8. Rizzetto M, Ponzetto A, Forzani I. Epidemiology of hepatitis delta virus: overview. ProgClinBiol Res 1991; 364: 1– 20.9. Sagnelli E, Stroffolini T, Ascione A, et al. Decrease in HDV endemicity in Italy. J Hepatol 1997; 26: 20– 4.10. Gaeta GB, Stroffolini T, Chiaramonte M, et al. Chronic hepatitis D: a vanishing disease? An Italian multicenter study. Hepatology 2000; 32 (Part 1): 824– 7.11. Navascues CA, Rodriguez M, Sotorrio NG, et al. Epidemiology of hepatitis D virus infection: changes in the last 14 years. Am J Gastroenterol 1995; 90: 1981– 4.12. Huo TI, Wu JC, Lin RY, et al. Decreasing hepatitis D virus infection in Taiwan: an analysis of contributory factors. J GastroenterolHepatol 1997; 12: 747– 51.13. Degertekin H, Yalcin K, Yakut M. The prevalence of hepatitis delta virus infection in acute and chronic liver diseases in Turkey: an analysis of clinical studies. Turk J Gastroenterol 2006; 17: 25– 34.14. Gaeta GB, Stroffolini T, Smedile A, Niro G, Mele A. Hepatitis delta in Europe: vanishing or refreshing? Hepatology 2007; 46: 1312– 3.15. Wedemeyer H, Heidrich B, Manns MP. Hepatitis D virus infection – not a vanishing disease in Europe!. Hepatology 2007; 45: 1331– 2; author reply 32–3.16. Le Gal F, Castelneau C, Gault E, et al. Hepatitis D virus infection – not a vanishing disease in Europe! – Reply. Hepatology 2007; 45: 1332– 3.17. Flodgren E, Bengtsson S, Knutsson M, et al. Recent high incidence of fulminant hepatitis in Samara, Russia: molecular analysis of prevailing hepatitis B and D virus strains. J ClinMicrobiol 2000; 38: 3311– 6.18. He LF, Ford E, Purcell RH, London WT, Phillips J, Gerin JL. The size of the hepatitis delta agent. J Med Virol. 1989;27:31–33.19. Ryu WS, Netter HJ, Bayer M, Taylor J. Ribonucleoprotein complexes of hepatitis delta virus. J Virol. 1993;67:3281–3287.20. Kos A, Dijkema R, Arnberg AC, van der Meide PH, Schellekens H. The hepatitis delta (delta) virus possesses a circular RNA. Nature. 1986;323:558–560.21. Wang KS, Choo QL, Weiner AJ, Ou JH, Najarian RC, Thayer RM, Mullenbach GT, Denniston KJ, Gerin JL, Houghton M. Structure, sequence and expression of the hepatitis delta (delta) viral genome. Nature. 1986;323:508–514. 22. Rafael AldabeAnimal Models of Chronic Hepatitis Delta Virus Infection Host–Virus Immunologic Interactionshttps://translated.turbopages.org/proxy_u/en-ru.ru.05bbea4f-649bdb0f-eee4b562-74722d776562/https/www.mdpi.com/2076-0817/4/1/46.23. Sureau C.The role of the HBV envelope proteins in the HDV replication cycle.Curr Top MicrobiolImmunol. 2006; 307: 113-13124. Wang C.J.ChenP.J.WuJ.C.PatelD.Chen D.S.Small-form hepatitis B surface antigen is sufficient to help in the assembly of hepatitis delta virus-like particles.J Virol. 1991; 65: 6630-663625. Dény P. Hepatitis delta virus genetic variability: from genotypes I, II, III to eight major clades?.Curr Top MicrobiolImmunol. 2006; 307: 151-17126. 26. Su C.W.HuangY.H.HuoT.I.ShihH.H.SheenI.J.Chen S.W.et al.Genotypes and viremia of hepatitis B and D viruses are associated with outcomes of chronic hepatitis D patients.Gastroenterology. 2006; 130: 1625-163527. Wu J.C. Functional and clinical significance of hepatitis D virus genotype II infection.Curr Top MicrobiolImmunol. 2006; 307: 173-18628. SmedileA.RizzettoM.Gerin J.L.Advances in Hepatitis D Virus Biology and Disease.in: Progress in Liver Disease. vol. XII. Saunders Company, 1994: 157-17529. HadziyannisS.J.HatzakisA.PapaioannouC.AnastassakosC.Vassiliadis E.Endemic hepatitis delta virus infection in a Greek community.ProgClinBiol Res. 1987; 234: 181-20230. Schaper M. Rodriguez-Frias F.JardiR.TaberneroD.HomsM.RuizG.QuerJ.Esteban R.Buti M.Quantitative longitudinal evaluations of hepatitis delta virus RNA and hepatitis B virus DNA shows a dynamic, complex replicative profile in chronic hepatitis B and D.J Hepatol. 2010; 52: 658-66431. CareddaF.AntinoriS.PastecchiaC.CoppinP.PallaM.PonzettoA.RizzettoM.Moroni M.Incidence of hepatitis delta virus infection in acute HBsAg-negative hepatitis.J Inf Dis. 1989; 159: 977-97932. FarciP.SmedileA.LavariniC.PiantinoP.CrivelliO.CaporasoN.TotiM.BoninoF.RizzettoM.Delta hepatitis in inapparent carriers of hepatitis B surface antigen. A disease simulating acute hepatitis B progressive to chronicity.Gastroenterology. 1983; 85: 669-67333. Taylor J.M.PurcellR.H.FarciP.Knipe D.M. Howley P. Fields virology. Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia201334. SmedileA.RosinaF.SaraccoG.ChiabergeE.LattoreV.Fabiano A.et al.Hepatitis B virus replication modulates pathogenesis of hepatitis D virus in chronic hepatitis D.Hepatology. 1991; 13: 413-41635. Wu J.C.ChenT.Z.HuangY.S.YenF.S.TingL.T.Sheng W.Y.et al.Natural history of hepatitis D viral superinfection: significance of viremia detected by polymerase chain reaction.Gastroenterology. 1995; 108: 796-80236. NiroG.A.SmedileA.FontanaR.OliveroA.CiancioA.ValvanoM.R.PittalugaF.CoppolaN.WedemeyerH.ZachouK.MarroneA.FasanoM.LottiG.AndreoneP.IacobellisA.AndriulliA.Rizzetto M.HBsAg kinetics in chronic hepatitis D during interferon therapy: on-treatment prediction of response.Aliment PharmacolTher. 2016; 44: 620-628 37. Casey JL. Control of ADAR1 editing of hepatitis delta virus RNAs.Curr Top MicrobiolImmunol. 2012;353:123–43. DOI: 10.1007/82_2011_146 38. Freitas N, Cunha C, Menne S, et al. Envelope proteins derived from naturally integrated hepatitis B virus DNA support assembly and release of infectious hepatitis delta virus particles. J Virol. 2014;88:5742–54. DOI: 10.1128/JVI.00430-14 39. Tu T, Budzinska MA, Shackel NA, et al. Hbv DNA integration: molecular mechanisms and clinical implications. Viruses. 2017;9:75. DOI: 10.3390/v9040075 40. Yan H, Zhong G, Xu G, et al. Sodium taurocholatecotransporting polypeptide is a functional receptor for human hepatitis B and D virus .Elife.2012;1:e00049. DOI: 10.7554/eLife.00049 41. Wedemeyer H, Bogomolov P, Blank A, et al. Final results of a multicenter, open-label phase 2B clinical trial to assess safety and efficacy of Myrcludex B in combination with tenofovir in patients with chronic HBV/HDV co-infection. J Hepatol. 2018;68:S3 DOI:10.1016/S0168-8278(18)30224-1 42. Wedemeyer H, Schöneweis K, Bogomolov PO, et al. 48 weeks of high dose (10 Mg) bulevirtide as monotherapy or with peginterferon alfa-2a in patients with chronic HBV/HDV co-infection. J Hepatol. 2020;73:S52–3.doi: 10.2147/JEP.S235550 43. Wedemeyer H, Port K, Deterding K, et al. A phase 2 dose-escalation study of lonafarnib plus ritonavir in patients with chronic hepatitis D: final results from the lonafarnib with ritonavir in HDV-4 (LOWR HDV-4) study. J Hepatol. 2017;66:S24.doi.org/10.1002/hep.32259 44. Koh C, Surana P, Han T, et al. A phase 2 study exploring once daily dosing of ritonavir boostedlonafarnib for the treatment of chronic delta hepatitis – end of study results from the LOWR HDV-3 study.JHepatol. 2017;66:S101–2. DOI:10.1016/S0168-8278(17)30464-6 45. Beilstein F, Blanchet M, Vaillant A, et al. Nucleic Acid Polymers Are Active against Hepatitis Delta Virus Infection In Vitro. J Virol. 2018;92(4):e01416-17. doi:10.1128/JVI.01416-17 46. Blanchet M, Sinnathamby V, Vaillant A, et al. Inhibition of HBsAg secretion by nucleic acid polymers in HepG2.2.15 cells. Antiviral Res. 2019;164:97–105. DOI: 10.1016/j.antiviral.2019.02.009 47. Bazinet M, Pântea V, Cebotarescu V, et al. Safety and efficacy of Rep 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (Rep 301 and Rep 301-LTF): a non-randomised, open-label, phase 2 tria. Lancet GastroenterolHepatol. 2017;2(12):877– 89. doi: 10.1016/S2468-1253(17)30288-1 48. Bazinet M, Pântea V, Cebotarescu V, et al. Persistent control of hepatitis B virus and hepatitis delta virus infection following Rep 2139-Ca and pegylated interferon therapy in chronic hepatitis B virus/hepatitis delta virus coinfection. HepatolCommun. 2021;5(2):189–202. doi: 10.1002/hep4.1633 49. Noordeen F, Scougall CA, Grosse A, Qiao Q, Ajilian BB, et al. Therapeutic Antiviral Effect of the Nucleic Acid Polymer REP 2055 against Persistent Duck Hepatitis B Virus Infection.PLoSOne. 2015;10(11):e0140909. DOI: 10.1371/journal.pone.0140909 50. Vaillant A. Rep 2139: antiviral mechanisms and applications in achieving functional control of HBV and HDV infection. ACS Infect Dis. 2019;5:675–87.DOI: 10.1021/acsinfecdis.8b00156